Association Between the C-Reactive Protein-Albumin-Lymphocyte Index and Endometriosis: Insights from the 1999-2006 National Health and Nutrition Examination Survey.
The C-reactive protein-albumin-lymphocyte (CALLY) index serves as an integrated indicator, reflecting the interplay between systemic inflammation, immune competence, and nutritional health. While validated in other chronic diseases, its relevance to …
Spontaneous Pneumothorax: A Review of Underlying Etiologies and Diagnostic Imaging Modalities.
This review focuses on the diverse etiologies of secondary spontaneous pneumothorax (SSP) and the crucial role of imaging in their diagnosis. Unlike primary spontaneous pneumothorax (PSP), which is typically due …
Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain.
Elagolix (ELA) 200 mg twice daily is an oral treatment approved for moderate-to-severe endometriosis-associated pain. However, the clinical use of ELA is limited by potential hypoestrogenic effects, including the loss …
Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight - The Malaysian Reserve
Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight The Malaysian Reserve
Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight - PR Newswire UK
Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight PR Newswire UK
Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight - Yahoo Finance
Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight Yahoo Finance
HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health - The Malaysian Reserve
HMI-115, a Potential First-in-Class Treatment for Endometriosis, Published Proof-of-Concept Phase II Clinical Trial Results in The Lancet Obstetrics, Gynaecology, & Women's Health The Malaysian Reserve